Napp Pharmaceuticals Limited

napp.co.uk

We’re a privately owned UK company with a strong track record in bringing high quality, innovative medicines to UK health professionals and their patients. We believe in excellence and delivering on our promises to the NHS, patients, our business partners and each other. We strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

DEARGEN ANNONUCES PATENT APPLICATION FOR A TNBC TARGET NOVEL DRUG CANDIDATE USING AI

Deargen Inc. | December 23, 2021

news image

Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it. Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of protein...

Read More

PHARMACY MARKET, PHARMA TECH

GOODRX EXPANDS PHARMACY SERVICES PLATFORM WITH $150M VITACARE ACQUISITION

GoodRx | October 21, 2022

news image

To circumvent overpriced prescription drugs and grow its robust pharmacy services platform, GoodRx finalized its vitaCare acquisition. Based on a transaction that started in the first quarter of 2022, GoodRx agreed to secure vitaCare for $150 million in cash. Based on vitaCare’s financial performance through 2023, an additional $7 million consideration is also possible. Read More

COVECTRA ANNOUNCES VRS FOR PHARMACEUTICAL MANUFACTURERS TO ENHANCE DRUG SUPPLY CHAIN SECURITY

Covectra | June 22, 2020

news image

Covectra, a leader in track and trace solutions, today announced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement. In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to ...

Read More

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

news image

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More
news image

Business Insights

DEARGEN ANNONUCES PATENT APPLICATION FOR A TNBC TARGET NOVEL DRUG CANDIDATE USING AI

Deargen Inc. | December 23, 2021

Deargen, a company specializing in the development of novel NCE drugs using artificial intelligence, announced on the 22rd that it had discovered and synthesized a new anticancer target compound using its own AI platform and had already applied for a patent for it. Deargen has the technology to predict candidates for a novel drug without the 3D structure data of proteins. Deargen's technology, which uses amino acid sequence data rather than the structure information of protein...

Read More
news image

PHARMACY MARKET, PHARMA TECH

GOODRX EXPANDS PHARMACY SERVICES PLATFORM WITH $150M VITACARE ACQUISITION

GoodRx | October 21, 2022

To circumvent overpriced prescription drugs and grow its robust pharmacy services platform, GoodRx finalized its vitaCare acquisition. Based on a transaction that started in the first quarter of 2022, GoodRx agreed to secure vitaCare for $150 million in cash. Based on vitaCare’s financial performance through 2023, an additional $7 million consideration is also possible. Read More

news image

COVECTRA ANNOUNCES VRS FOR PHARMACEUTICAL MANUFACTURERS TO ENHANCE DRUG SUPPLY CHAIN SECURITY

Covectra | June 22, 2020

Covectra, a leader in track and trace solutions, today announced the Covectra Verification Router Service (VRS), a complete API solution enabling pharmaceutical brands to validate the status of a returned product to ascertain its resell ability and ensure regulatory compliance with the upcoming Drug Supply Chain and Security Act (DSCSA) saleable returns requirement. In November 2020, the FDA enforcement will begin as pharmaceutical distributors of regulated medicines will need to ...

Read More
news image

Pharmacy Market

ASTELLAS ANNOUNCES TOPLINE RESULTS FROM PHASE 3 LONG-TERM SAFETY STUDY OF FEZOLINETANT IN MAINLAND CHINA

Astellas Pharma Inc. | September 05, 2022

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause. MOONLIGHT 3 is a 52-week single-arm Phase 3 clinical trial ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us